Leptin: Less Is More
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
The successful use of leptin for the treatment of individuals with lipodystrophy and leptin deficiency is well established. However, pharmacological approaches of leptin therapy for the treatment of diet-induced obesity have been ineffective. There is ample room for a better understanding of the much famed “leptin resistance” phenomenon. Our recent data in this area prompt us to call for a conceptual shift. This shift entails a model in which a reduction of bioactive leptin levels in the context of obesity triggers a high degree of leptin sensitization and improved leptin action, both centrally and peripherally. Put another way, hyperleptinemia per se causes leptin resistance and associated metabolic disorders. In this perspective, we briefly discuss the underlying conceptual steps that led us to explore partial leptin reduction as a viable therapeutic avenue. We hope this discussion will contribute to potential future applications of partial leptin reduction therapy for the treatment of obesity and type 2 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The MR-Base platform supports systematic causal inference across the human phenome
Hemani, G., Zheng, J., Elsworth, B., Wade, K. H., Haberland, V., Baird, D., Laurin, C., Burgess, S., Bowden, J., Langdon, R., et al. (2018) · eLife · doi:10.7554/elife.34408 · Cited by 7,959
Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
Nissen, S. E., & Wolski, K. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072761 · Cited by 4,675 · cited 1×
“This collectively dampened the enthusiasm for the wide usage of rosiglitazone in the treatment of individuals with type 2 diabetes (61).”
BackgroundRole of leptin in the neuroendocrine response to fasting
Ahima, R. S., Prabakaran, D., Mantzoros, C., Qu, D., Lowell, B., Maratos-Flier, E., & Flier, J. S. (1996) · Nature · doi:10.1038/382250a0 · Cited by 3,117
Long-term persistence of hormonal adaptations to weight loss
Sumithran, P., Prendergast, L. A., Delbridge, E., Purcell, K., Shulkes, A., Kriketos, A., & Proietto, J. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1105816 · Cited by 1,449 · cited 1×
“Thus, dropping leptin levels has been proposed as a cause of body weight rebound (45).”
BackgroundAhima, R. S., & Flier, J. S. (2000) · Annual Review of Physiology · doi:10.1146/annurev.physiol.62.1.413 · Cited by 1,428
Leptin-Replacement Therapy for Lipodystrophy
Oral, E. A., Simha, V., Ruiz, E., Andewelt, A., Premkumar, A., Snell, P., Wagner, A. J., DePaoli, A. M., Reitman, M. L., Taylor, S. I., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012437 · Cited by 1,247 · cited 1×
“Food and Drug Administration–approved treatment of individuals with leptin deficiency and generalized lipodystrophy (13).”
BackgroundInterleukin-6-deficient mice develop mature-onset obesity
Wallenius, V., Wallenius, K., Ahrén, B., Rudling, M., Carlsten, H., Dickson, S. L., Ohlsson, C., & Jansson, J.-O. (2002) · Nature Medicine · doi:10.1038/nm0102-75 · Cited by 1,213 · cited 1×
“Similarly, interleukin-6 has been shown to attenuate obesity in a leptin-dependent manner (38).”
BackgroundPhysiological response to long-term peripheral and central leptin infusion in lean and obese mice.
Halaas, J. L., Boozer, C., Blair-West, J., Fidahusein, N., Denton, D. A., & Friedman, J. M. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.16.8878 · Cited by 1,033
Identification of SOCS-3 as a Potential Mediator of Central Leptin Resistance
Bjørbæk, C., Elmquist, J. K., Frantz, J. D., Shoelson, S. E., & Flier, J. S. (1998) · Molecular Cell · doi:10.1016/s1097-2765(00)80062-3 · Cited by 1,014 · cited 5×
“The key feedback mechanisms are executed by the suppressor of cytokine signaling 3 (SOCS3) and phosphatases, including protein tyrosine phosphatase 1B (PTP1B) and T-cell protein tyrosine phosphatase (TCPTP) (51,52).”
BackgroundInfluentialSelf-citationLeptin Regulation of Neuroendocrine Systems
Ahima, R. S., Saper, C. B., Flier, J. S., & Elmquist, J. K. (2000) · Frontiers in Neuroendocrinology · doi:10.1006/frne.2000.0197 · Cited by 767 · cited 1×
“, leptin) reflect an energy deficit and prompt increased food intake and decreased energy expenditure (30).”
BackgroundSelf-citation
Cited by
Adiponectin, Leptin and Cardiovascular Disorders
Zhao, S., Kusminski, C. M., & Scherer, P. E. (2021) · Circulation Research · doi:10.1161/circresaha.120.314458 · Cited by 373
Self-citationGlucagon-like peptide-1 receptor co-agonists for treating metabolic disease.
Baggio, L. L., & Drucker, D. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101090 · Cited by 299
A review of current guidelines for the treatment of obesity
(2022) · The American Journal of Managed Care · doi:10.37765/ajmc.2022.89292 · Cited by 207
A feed-forward regulatory loop in adipose tissue promotes signaling by the hepatokine FGF21
Han, M. S., Perry, R. J., Camporez, J.-P., Scherer, P. E., Shulman, G. I., Gao, G., & Davis, R. J. (2021) · Genes & Development · doi:10.1101/gad.344556.120 · Cited by 43
Self-citationLiu, Y., & Gong, F. (2025) · Phytotherapy Research · doi:10.1002/ptr.8415 · Cited by 6
“The primary component of its water-soluble extracts is safflower yellow (SY), with hydroxysafflor yellow A (HSYA) identified as the active monomer of SY (Zhao et al. 2020b).”
Metadata
- Authors
- Zhao, S., Kusminski, C. M., Elmquist, J. K., & Scherer, P. E.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2020-04-13
- Volume
- 69
- Issue
- 5
- Pages
- 823-829
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W3016618011
- Cited by
- 123
- References
- 22
- FWCI
- 6.76
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Leptin: Less Is More. https://app.cochat.ai/papers/10.2337/dbi19-0018
- The paper
- Zhao, S., Kusminski, C. M., Elmquist, J. K., & Scherer, P. E. (2020). Leptin: Less Is More. Diabetes. https://doi.org/10.2337/dbi19-0018
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.